Sentences with phrase «research in tumor immunology»

CRI will present the 2016 William B. Coley Award for Distinguished Research in Tumor Immunology to Ton N. Schumacher, Ph.D., for his contributions to our understanding of how immune cells identify and target tumor - specific neoantigens, and how this capability can provide anti-tumor immunity.

Bryan Choi, the recipient of a Student Training and Research in Tumor Immunology (STaRT) grant at Duke University, is working to develop a new strategy using Bispecific T cell Engagers (BiTEs) to treat glioblastoma.

He received the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology and the 2017 Warren Alpert Foundation award for this work, which led to development of the PD - 1 pathway blockade for cancer immunotherapy.

Not exact matches

«Pancreatic cancer cells are deadly because they program nearby immune cells to permit the tumors to survive and grow,» says study author George Miller, MD, head of the Cancer Immunology Program at Perlmutter and vice chair for research in the Department of Surgery at NYU Langone.

«Resveratrol may have detrimental effects in some disease conditions and should be discouraged for supplemental use by MS patients pending further research,» says lead investigator Ikuo Tsunoda, MD, PhD, Assistant Professor in the Department of Microbiology and Immunology, Center for Molecular & Tumor Virology of the Louisiana State University Health Sciences Center, Shreveport, LA.

This led to development of newer technology, called single cell sequencing (SCS), that has had a major impact in many areas of biology, including cancer research, neurobiology, microbiology, and immunology, and has greatly improved understanding of certain tumor characteristics in cancer.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

«Our research shows that the protein GSK3 plays a crucial role in helping B cells meet the energy needs of their distinct states,» says Robert Rickert, Ph.D., director of the Tumor Microenvironment and Cancer Immunology Program at Sanford Burnham Prebys Medical Discovery Institute (SBP).

Cancer Research Institute inaugurates its Investigator Award Program for junior faculty members working in immunology and tumor immunology.

The Clinical Accelerator, building on 60 + years of CRI's dedication to funding the most innovative basic science in tumor immunology, enables experts to advance their most ambitious clinical and translational research ideas to cure cancer, and accelerates studies that one group or company could not do alone.

He has research experience in Rheumatology, Tumor Immunology and Salmonellosis / Typhoid Fever.

She trained in tumor immunology as a senior clinical and research fellow before joining the faculty at Johns Hopkins University in 2001.

The Clinical Accelerator network includes approximately 80 of the world's leading physician - scientists with expertise in tumor immunology and cancer immunotherapy clinical trials, immune monitoring, and correlative research.

Concise review: Humanized models of tumor immunology in the 21st century: Convergence of cancer research and tissue engineering.

Research in the Immunology, Microenvironment and Metastasis program is aimed at 1) merging basic mechanistic understanding of multidisciplinary pathways of host - tumor interactions and metastatic dissemination with novel translational opportunities for diseases diagnosis and immunotherapy, as well as 2) investigating mechanisms regulating immune responses in cancer and their potential therapeutic manipulation.

The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept..

Fascinated by human immunology and translational research, I undertook my PhD in tumor immunology at the University of Tuebingen (Germany).

He was named 2006 «Australian of the Year» and was joint winner of CRI's prestigious William B. Coley Award for Distinguished Research in Basic and Tumor Immunology.

CRI Scientific Advisory Council director Lloyd J. Old, M.D., a pioneer responsible for many seminal discoveries in the field, is a senior expert in tumor immunology who for the past four decades has guided the scientific vision for CRI and who currently leads the Institute's global cancer vaccine research programs.

In 2016, Dmitry I. Gabrilovich, M.D., Ph.D., program leader of Wistar's Translational Tumor Immunology program, and his research team identified a marker for myeloid - derived suppressor cells (MDSCs), a population of immune cells implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapIn 2016, Dmitry I. Gabrilovich, M.D., Ph.D., program leader of Wistar's Translational Tumor Immunology program, and his research team identified a marker for myeloid - derived suppressor cells (MDSCs), a population of immune cells implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotheTumor Immunology program, and his research team identified a marker for myeloid - derived suppressor cells (MDSCs), a population of immune cells implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapin tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunothetumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy.

Using expertise in genomics and cell biology, Dr. Pillai is looking forward to expanding his research in the field of Tumor Immunology, with focus on Breast Cancer.

From home base in the Arnold and Mabel Beckman Center for Cancer Immunotherapeutics & Tumor Immunology, Naranjo and Wagner can look across the way to CIty of Hope Helford Clinical Research Hospital, where patients in trials receive infusions of therapeutic CAR T cells.

Following graduation, performed research and received a M.S. in tumor immunology at Roswell Park Cancer Institute in Buffalo, NY in 2012.